Skip to main content

COVID-19 Advisory: Visitor restrictions are in place for all Phoenix Children’s locations. Masks are required for all visitors and for patients ages 2+. For more information, visit our COVID-19 Resource Center.

Michael M. Henry, MD

Edit Profile

Michael M. Henry, MD

Edit Profile

Specialty

Areas of Expertise

  • Pediatric Hematology Pediatric Oncology Liquid Tumors Hodgkin Lymphomas Non-Hodgkin Lymphomas Histiocytosis Benign Blood Disorder

About Michael M. Henry, MD

As a pediatric hematologist/oncologist, Michael Henry, MD, specializes in treating blood cancers and other blood diseases. Dr. Henry is the section chief of the Liquid Tumor Program in the Center for Cancer and Blood Disorders, the director of the Early Drug Development Program, and the director of the Histiocytosis Program.

Dr. Henry serves as an associate professor of child health at the University of Arizona College of Medicine.

Growing up, Dr. Henry knew he wanted to help kids and build long-term relationships with them and their families, just like his pediatrician did. The opportunity to start a hematology/oncology fellowship training program led him to choose Phoenix Children's. The challenge of finding cutting-edge cancer treatment and the opportunity to work alongside a dedicated team inspires him to stay.

...Read more

As a pediatric hematologist/oncologist, Michael Henry, MD, specializes in treating blood cancers and other blood diseases. Dr. Henry is the section chief of the Liquid Tumor Program in the Center for Cancer and Blood Disorders, the director of the Early Drug Development Program, and the director of the Histiocytosis Program.

Dr. Henry serves as an associate professor of child health at the University of Arizona College of Medicine.

Growing up, Dr. Henry knew he wanted to help kids and build long-term relationships with them and their families, just like his pediatrician did. The opportunity to start a hematology/oncology fellowship training program led him to choose Phoenix Children's. The challenge of finding cutting-edge cancer treatment and the opportunity to work alongside a dedicated team inspires him to stay.

Dr. Henry is board certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics. In addition, he is a member of the Children's Oncology Group, the American Society of Pediatric Hematology/Oncology and the Histiocyte Society.

After earning his medical degree at Jefferson Medical College of Thomas Jefferson University, Dr. Henry completed a pediatric residency at Thomas Jefferson University Hospital/A.I. DuPont Hospital for Children. He also completed a pediatric hematology/oncology fellowship at Children's National Medical Center.

Among Dr. Henry's achievements are developing a fellowship training program at Phoenix Children's Center for Cancer and Blood Disorders and receiving the Melvin L. Cohen, MD, Faculty Teacher of the Year Award.

Dr. Henry contributes to advancing his field through research. He is published in numerous professional journals and has been an invited speaker at regional, national and international seminars and meetings.

When it comes to patient care, Dr. Henry believes patients and their families deserve his undivided attention. He listens with compassion and believes every child deserves a chance to be a child without the worry of a chronic disease. That may mean thinking outside the box when faced with a challenging diagnosis or treatment.

When he's not working, Dr. Henry enjoys learning website development and iPhone programming. He also enjoys playing racquetball, traveling and learning about different world cultures.

Read less

+Education & Training

Board Certification

Pediatrics, Hematology/Oncology

Medical School / Education

Jefferson Medical College of Thomas Jefferson University

Residency

Thomas Jefferson University Hospital/A.I. DuPont Hospital for Children Pediatrics

Fellowship

Children's National Medical Center Hematology/Oncology

+Academic and Professional Affiliations

Academic Affiliations

Assistant Professor of Clinical Pediatrics, Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona; Assistant Professor of Pediatrics, Department of Pediatrics, Mayo College Of Medicine, Rochester, Minnesota; Assistant Professor of Pediatrics, Department of Pediatrics, Creighton University School of Medicine, Phoenix, Arizona

Professional Affiliations

Children's Oncology Group, American Society of Pediatric Hematology/Oncology; Histiocyte Society

+Awards

  • Faculty Teacher of the Year (Phoenix Children's Hospital) 2005-2006

+Research & Publications

Goode E, Smith JA, Gilpatrick M, Matney C, Borch-Christensen B, Henry MM. Autoimmune lymphoproliferative syndrome with Langerhans cell histiocytosis diagnosis. Pediatr Blood Cancer. 2022; 69(1):e29301. https://pubmed.ncbi.nlm.nih.gov/34398530/

McInnis-Smith K, Mansueto LA, Schafernak K, Jacobsen J, Henry MM, Ramasubramanian A. Isolated optic nerve leukemic relapse diagnosed via fine needle aspiration biopsy and transconjunctival biopsy. Pediatr Blood Cancer. 2021; 68(2):e28684. https://pubmed.ncbi.nlm.nih.gov/32886399/

Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Dapena DJL, Henry M, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. New England Journal of Medicine. 2020; 382(19):1811-1822. https://pubmed.ncbi.nlm.nih.gov/32374962/

Chaturvedi V, Marsh RA, Zoref-Lorenz A, Owsley E, Chaturvedi V, Nguyen TC, Goldman JR, Henry MM, et al. (2021). T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021; 137(17):2337-2346. https://pubmed.ncbi.nlm.nih.gov/33512385/

Lin H, Scull BP, Goldberg B, Abhyankar H, Eckstein OS, Zinn D, Lubega J, Agrusa J, El-Mallawanay NK, Gulatu N, Forbes LR, Chinn IK, Chakraborty R, Velasquez J, Goldman J, Bashir DA, Lam FW, Muscal E, Henry MM, et al. IFN-? Signature in the Plasma Proteome Distinguishes Pediatric Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS. Blood Advances. 2021; 5(17):3457-3467. https://pubmed.ncbi.nlm.nih.gov/34461635/

Lymphoma/Leukemia; Lymphoproliferative Disease; Histiocytic Disorders; Benign Hematology; Technology in the Workplace<br/>
Share this page